EC Number   |
Inhibitors |
Structure |
|---|
   1.5.1.33 | (-)-epicatechin-3-gallate |
- |
   |
| 1.5.1.33 | (1R,4S,6R)-4-hydroxy-3-methyl-6-(propan-2-yl)cyclohex-2-en-1-yl 5beta,8alpha,10alpha,13alpha-kaura-9(11),16-dien-18-oate |
- |
|
| 1.5.1.33 | (1R,4S,6R)-4-hydroxy-3-methyl-6-(propan-2-yl)cyclohex-2-en-1-yl 5beta,8alpha,9beta,10alpha,13alpha-kaur-16-en-18-oate |
- |
|
| 1.5.1.33 | (2-amino-2,3-dihydro-1H-benzimidazol-1-yl)(phenyl)methanone |
- |
|
| 1.5.1.33 | (2E,4E)-N-(2-methylpropyl)dodeca-2,4-dienamide |
- |
|
| 1.5.1.33 | (2E,4E)-N-(2-methylpropyl)octadeca-2,4-dienamide |
- |
|
| 1.5.1.33 | (2E,4E,12E)-13-(benzo[d][1,3]dioxol-5-yl)-N-isobutyltrideca-2,4,12-trienamide |
- |
|
| 1.5.1.33 | (4-fluoro-phenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid ethyl ester |
- |
|
| 1.5.1.33 | (4-fluoro-phenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid ethyl ester |
treatment with 98 microM resulted in reduction of viable cells from 96.5% (control) to 9.86% after 5 h |
|
| 1.5.1.33 | (4S)-4-[[(4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]phenyl)carbonyl]amino]-5-oxohexanoic acid |
- |
|
